We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Asuragen Receives Certification for Gene Expression Profiling

By Biotechdaily staff writers
Posted on 28 Feb 2007
Illumina, Inc. More...
(San Diego, CA, USA) and Asuragen, Inc. (Austin Texas, USA) have announced that Asuragen has successfully completed Illumina Certified Service Provider (CSPro) certification for gene expression profiling.

Asuragen is the first commercial service provider to offer Illumina gene expression profiling services. Illumina provides next-generation tools for the large-scale analysis of genetic variation and function.

"In response to customer requests, we are pleased to offer an additional choice in gene expression profiling with the Illumina platform,” said Rollie Carlson, President of Asuragen. "The work performed by Asuragen and Illumina to demonstrate proficiency in the CSPro program will assure customers quality data.”

Combined with Asuragen's sample preparation, scientists can perform gene expression profiling from low amounts of starting sample, including those traditionally used in clinical settings, such as biopsies, fine needle aspirates, etc. Data from the Illumina platform are compatible with Asuragen's Standard Service Premium and Pathways Analysis Services.

"Our commitment to quality and innovative technologies is what inspired us to become an Illumina CSPro. The Illumina platform allows us to provide solutions to the experimental needs of our customers,” said Scott Hunicke-Smith, vice president and general manager of Asuragen Services.

"Recent results from the MicroArray Quality Control project confirmed that Illumina's gene expression technology is capable of generating excellent quality and performance, and boosting the number of detected genes,” he continued.


Related Links:
Illumina
Asuragen

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.